<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274452</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-113-1908</org_study_id>
    <nct_id>NCT04274452</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)</brief_title>
  <acronym>ADVANCE2</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>argenx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate&#xD;
      the efficacy and safety of ARGX-113 in patients with primary ITP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The ARGX-113-1908 study will be replaced by a similar design with a subcutaneous formulation&#xD;
    (ARGX-113-2004)&#xD;
  </why_stopped>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of cumulative weeks over the planned 24 week treatment period with platelet counts of ≥50×10^9/L in patients with chronic ITP.</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥50×10^09/L in the overall population (chronic and persistent ITP).</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the overall population with a sustained platelet count response defined as achieving platelet counts of ≥50×10^9/L for at least 4 of the 6 visits between week 19 and 24 of the trial</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the overall population achieving platelet counts of ≥50×10^9/L for at least 6 of the 8 visits between week 17 and 24 of the trial</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the overall population with overall platelet count response defined as achieving a platelet count of ≥50×10^9/L on at least 4 occasions at any time during the treatment period</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of disease control defined as the number of cumulative weeks until week 12, with platelet counts of ≥50×10^9/L in the overall population</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the overall population with overall platelet count response defined as achieving a platelet count of ≥50×10^9/L on at least 4 occasions at any time until week 12</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in platelet count at each visit in the overall population.</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response defined as the time to achieve 2 consecutive platelet counts of ≥50×10^9/L in the overall population</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of cumulative weeks over the treatment period with platelet counts of ≥30×10^9/L and ≥20×10^9/L above baseline in the overall population</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients with baseline platelet count of &lt;15×10^9/L, the number of cumulative weeks over the treatment period with platelet counts of ≥30×10^9/L and ≥20×10^9/L above baseline in the overall population</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of the World Health Organization (WHO)-classified bleeding events in the overall population</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of receipt of rescue therapy (rescue per patient per month)</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients for whom dose and/or frequency of concurrent ITP therapies have increased at week 12 or later</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (AEs), AEs of special interest (AESIs)and serious AEs (SAEs).</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs, electrocardiogram (ECG), and laboratory assessments</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PRO (FACIT-Fatigue, Fact-Th6) at planned visits</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in QoL (SF-36) at planned visits</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (ADA) to efgartigimod</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of efgartigimod : maximum observed serum concentration (Cmax)</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of efgartigimod : serum concentration observed predose (Cthrough)</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics markers: total immunoglobulin (Ig) G, IgG isotypes (IgG1, IgG2, IgG3, IgG4), antiplatelet antibody levels</measure>
    <time_frame>Up to 31 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Primary Immune Thrombocytopenia (ITP)</condition>
  <arm_group>
    <arm_group_label>efgartigimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving an intravenous infusion of efgartigimod</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving an intravenous infusion of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>efgartigimod</intervention_name>
    <description>Intravenous infusion of efgartigimod</description>
    <arm_group_label>efgartigimod</arm_group_label>
    <other_name>ARGX-113</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion of placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to understand the requirements of the trial and provide written informed&#xD;
             consent (including consent for the use and disclosure of research related health&#xD;
             information), willing and able to comply with the trial protocol procedures (including&#xD;
             attending the required trial visits).&#xD;
&#xD;
          -  Male/female aged ≥18 years at the time the informed consent form (ICF) is signed.&#xD;
&#xD;
          -  Confirmed diagnosis of ITP made at least 3 months before randomization and based on&#xD;
             the American Society of Hematology Criteria, and without a known etiology for&#xD;
             thrombocytopenia.&#xD;
&#xD;
          -  Diagnosis supported by a response to a prior ITP therapy (other than TPO RAs), in the&#xD;
             opinion of the investigator.&#xD;
&#xD;
          -  Mean platelet count of &lt;30×10^9/L from 2 counts during the screening period including&#xD;
             the predose count at visit 1. Additionally, a documented history of a platelet count&#xD;
             of &lt;30×109/L prior to screening.&#xD;
&#xD;
          -  At the start of the trial, the patient either takes concurrent ITP treatment(s) and&#xD;
             has received at least 1 prior therapy for ITP in the past, or the patient does not&#xD;
             take treatment for ITP but has received at least 2 prior treatments for ITP. Patients&#xD;
             receiving permitted concurrent ITP treatment(s) at baseline, must have been stable in&#xD;
             dose and frequency for at least 4 weeks prior to randomization. Permitted concurrent&#xD;
             ITP medications include oral corticosteroids, oral immunosuppressants,&#xD;
             dapsone/danazol, fostamatinib, and/or oral TPO-RAs. Patients not receiving concurrent&#xD;
             ITP therapy are also eligible for the trial if they have not received prior ITP&#xD;
             therapy for at least 4 weeks prior to baseline, and 6 months in case of prior ITP&#xD;
             therapy with an anti-CD20 therapy (eg, rituximab).&#xD;
&#xD;
          -  Women of childbearing potential: Women of childbearing potential must have a negative&#xD;
             serum pregnancy test at screening and a negative urine pregnancy test at baseline&#xD;
             before trial medication can be administered. Women must be on a stable regimen for at&#xD;
             least 1 month of at least 1 highly effective method of contraception (ie, failure rate&#xD;
             of less than 1% per year) during the trial and for 90 days after the last&#xD;
             administration of the IMP.&#xD;
&#xD;
          -  Non-sterilized male patients who are sexually active with a female partner of&#xD;
             childbearing potential must use effective contraception from signing the ICF through&#xD;
             90 days after the last administration of the IMP. Male patients practicing true sexual&#xD;
             abstinence (as consistent with preferred and usual lifestyle) can be included.&#xD;
             Sterilized male patients who have had a vasectomy and with documented absence of sperm&#xD;
             postprocedure can be included. Male patients are not allowed to donate sperm from&#xD;
             signing the ICF through 90 days after the last dose of the IMP.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ITP/thrombocytopenia associated with another condition, eg, lymphoma, chronic&#xD;
             lymphocytic leukemia, viral infection, hepatitis, induced or alloimmune&#xD;
             thrombocytopenia, or thrombocytopenia associated with myeloid dysplasia.&#xD;
&#xD;
          -  Use of anticoagulants (eg, vitamin K antagonists, direct oral anticoagulants) within 4&#xD;
             weeks prior to randomization.&#xD;
&#xD;
          -  Use of any transfusions within 4 weeks prior to randomization.&#xD;
&#xD;
          -  Use of Ig (IV, subcutaneous, or intramuscular route) or plasmapheresis (PLEX), 4 weeks&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Use of romiplostim within 4 weeks prior to randomization.&#xD;
&#xD;
          -  Undergone splenectomy less than 4 weeks prior to randomization.&#xD;
&#xD;
          -  Use of an investigational product within 3 months or 5 half-lives (whichever is&#xD;
             longer) before the first dose of the IMP.&#xD;
&#xD;
          -  Use of any monoclonal antibody within the 6 months before the first dose of the IMP.&#xD;
&#xD;
          -  At the screening visit, clinically significant laboratory abnormalities as below:&#xD;
             Hemoglobin ≤9 g/dL - OR - International normalized ratio &gt;1.5 or activated partial&#xD;
             thromboplastin time &gt;1.5×ULN - OR - Total IgG &lt;6 g/L.&#xD;
&#xD;
          -  History of malignancy unless deemed cured by adequate treatment with no evidence of&#xD;
             recurrence for ≥3 years before the first administration of the IMP. Patients with the&#xD;
             following cancer can be included at any time: Adequately treated basal cell or&#xD;
             squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the&#xD;
             breast, Incidental histological finding of prostate cancer (TNM stage T1a or T1b)&#xD;
&#xD;
          -  Uncontrolled hypertension, defined as a repeated elevated blood pressure exceeding 160&#xD;
             mmHg (systolic) and/or 100 mmHg (diastolic) despite appropriate treatments.&#xD;
&#xD;
          -  History of a major thrombotic or embolic event (eg, myocardial infarction, stroke,&#xD;
             deep venous thrombosis, or pulmonary embolism) within 12 months prior to&#xD;
             randomization.&#xD;
&#xD;
          -  History of coagulopathy or hereditary thrombocytopenia or a family history of&#xD;
             thrombocytopenia.&#xD;
&#xD;
          -  Clinical evidence of other significant serious diseases, have had a recent major&#xD;
             surgery, or who have any other condition in the opinion of the investigator, that&#xD;
             could confound the results of the trial or put the patient at undue risk.&#xD;
&#xD;
          -  Positive serum test at screening for an active viral infection with any of the&#xD;
             following conditions: Hepatitis B virus (HBV) that is indicative of an acute or&#xD;
             chronic infection, Hepatitis C virus (HCV) based on HCV-antibody assay, Human&#xD;
             immunodeficiency virus (HIV) based on test results that are associated with an&#xD;
             acquired immunodeficiency syndrome (AIDS)-defining condition or a CD4 count &lt;200&#xD;
             cells/mm3.&#xD;
&#xD;
          -  Clinical evidence of significant unstable or uncontrolled acute or chronic diseases&#xD;
             other than ITP (eg, cardiovascular, pulmonary, hematologic, gastrointestinal,&#xD;
             endocrine, hepatic, renal, neurological, malignancy, infectious diseases, uncontrolled&#xD;
             diabetes) despite appropriate treatments, which could put the patient at undue risk.&#xD;
&#xD;
          -  Known hypersensitivity reaction to efgartigimod or 1 of its excipients.&#xD;
&#xD;
          -  Previously participated in a clinical trial with efgartigimod.&#xD;
&#xD;
          -  Pregnant or lactating females and those who intend to become pregnant during the trial&#xD;
             or within 90 days after last dose of the IMP.&#xD;
&#xD;
          -  Clinically significant uncontrolled active or chronic bacterial, viral, or fungal&#xD;
             infection at screening.&#xD;
&#xD;
          -  Any other known autoimmune disease that, in the opinion of the investigator, would&#xD;
             interfere with an accurate assessment of clinical symptoms of ITP or put the patient&#xD;
             at undue risk.&#xD;
&#xD;
          -  Current or history of (ie, within 12 months of screening) alcohol, drugs, or&#xD;
             medication abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>September 11, 2020</last_update_submitted>
  <last_update_submitted_qc>September 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

